Acute Hemolytic Transfusion Reaction (AHTR), anti-A2

Ready to upload
Record number: 
Adverse Occurrence type: 
MPHO Type: 
Estimated frequency: 
Case Report
Time to detection: 
1 hour
Alerting signals, symptoms, evidence of occurrence: 
Patient with blood group B was incorrectly transfused with a unit of A2 group red blood cells, and developed clinical and immunohematologic reactions; patient was treated with eculizumab, but hemoglobinemia and hemoglobinuria was present several hours after transfusion.
Demonstration of imputability or root cause: 
Hemoglobinuria, hemoglobemia, transient increased bilirubin.
Imputability grade: 
2 Probable
Groups audience: 
Suggest new keywords: 
anti-A2, acute hemolytic transfusion reaction (AHTR),
Reference attachment: 
Suggest references: 
Weinstock, C., Mohle, R., Dorn, C., Weisel, K., Hchsmann, B., Schrezenmeier, H. and Kanz, L. (2014). Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO-incompatible red blood cell transfusion, Transfusion 55(3):605-610. DOI: 10.1111/trf.12882;